Novo Nordisk A S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
- Symbol
- NVO
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- 52 week range
- 35.12 - 64.16
Valuation
- Share price
- $37.40 (close of 2026-10-01)
- P/E (TTM)
- 10.88x
- Price to book
- 5.75x
- Price to free cash flow
- 18.91x
Price performance
| Period | Change |
|---|---|
| 1 day | -1.35% |
| 5 days | -3.16% |
| 1 month | -17.11% |
| 3 months | -23.31% |
| 6 months | +2.52% |
| Year to date | -26.49% |
| 1 year | -36.79% |
| 3 years | -58.87% |
| 5 years | -21.99% |
| 10 years | +79.81% |
| All time | +23275.00% |
Members of Congress who disclosed NVO trades
Lisa McClain · Scott Franklin · Marjorie Taylor Greene · Byron Donalds · Kevin Hern · Alan Armstrong · Laurel Lee · Val Hoyle
Super investors holding NVO
Sarah Ketterer (Causeway Capital Management LLC)
Profitability and growth
- Return on equity
- 52.79%
- Return on invested capital
- 33.35%
- Return on assets
- 18.87%
- Return on capital employed
- 39.01%
- Gross margin
- 80.98%
- Net margin
- 33.14%
- EBITDA margin
- 46.05%
- Revenue growth
- 6.43%
- Net income growth
- 1.43%
- Free cash flow growth
- -20.11%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 5.29%
- Current ratio
- 0.80x
- Net debt to EBITDA
- 0.70x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Shares outstanding
- 4.44B
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 80.98% | 33.14% | 52.79% | 33.35% |
| 2024-12-31 | 84.67% | 34.78% | 70.38% | 44.29% |
| 2023-12-31 | 84.60% | 36.03% | 78.53% | 68.46% |
| 2022-12-31 | 83.92% | 31.38% | 66.51% | 63.42% |
| 2021-12-31 | 83.20% | 33.92% | 67.50% | 52.12% |
| 2020-12-31 | 83.51% | 33.19% | 66.54% | 66.23% |
| 2019-12-31 | 83.54% | 31.92% | 67.63% | 101.66% |
| 2018-12-31 | 84.25% | 34.54% | 74.52% | 105.66% |
| 2017-12-31 | 84.21% | 34.14% | 0.00% | - |
| 2016-12-31 | 84.63% | 33.93% | 0.00% | - |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-08-04 | Jun/2026 | - |
| 2026-05-06 | - | - |
| 2026-02-04 | - | - |
| 2025-11-05 | - | - |
| 2025-08-06 | - | - |
| 2025-05-07 | - | - |
| 2025-02-05 | - | - |
| 2024-11-06 | - | - |
Filings and sources
- Company website
- novonordisk.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
GSK plc (GSK) · Organon & Co. (OGN) · Biogen Inc. (BIIB) · Bristol Myers Squibb Co (BMY) · Teva Pharmaceutical Industries Ltd (TEVA) · Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades